Wyszuk. zaawans.

Tom 9, Nr 5 (2024)
Artykuł przeglądowy
Opublikowany online: 2024-11-15

dostęp otwarty

Pokaż PDF (angielski) Pobierz plik PDF
Wyświetlenia strony 14
Wyświetlenia/pobrania artykułu 7
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Obesity in breast cancer patients after oncological treatment. How to conduct a nutritional intervention?

Nikola Janowska12, Agata Łyczek13, Natalia Komorniak1, Natalia Jakubiak1, Karolina Siedlecka-Kaźmierczak4, Ewa Stachowska1
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2024;9(5):368-376.

Streszczenie

Obesity in breast cancer patients is a significant predictor of morbidity as well as adverse treatment outcomes. It correlates with poorer response to treatment, particularly affecting survival length and quality of life. This paper aims to describe the relationship between obesity and breast cancer prognosis, highlighting the importance of integrated prehabilitation strategies. Prehabilitation, which includes nutritional counseling, psychological support, and physical activity, is proposed as a proactive approach to prepare patients for the rigors of cancer treatment, such as surgery, chemotherapy, and radiation therapy. The results emphasize the need to maintain optimal weight and body compo­sition through dietary adjustments, particularly high protein intake, and physical rehabilitation. An interdisciplinary approach, including the involvement of oncologists, nutritionists, psychologists, and physiotherapists, is crucial for successful treatment outcomes.

Słowa kluczowe: obesity breast cancerprehabilitation

Artykuł dostępny w formacie PDF

Pokaż PDF (angielski) Pobierz plik PDF

Referencje

  1. Mazur-Roszak M, Litwiniuk M, Grodecka-Gazdecka S. Obesity and breast cancer. Współczesna Onkologia. 2010; 4: 270–275.
    CrossRef
  2. Arends J, Bodoky G, Bozzetti F, et al. DGEM (German Society for Nutritional Medicine), ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr. 2006; 25(2): 245–259.
    CrossRefPubMed
  3. Pischon T, Nöthlings U, Boeing H. Obesity and cancer. Proc Nutr Soc. 2008; 67(2): 128–145.
    CrossRefPubMed
  4. Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014; 25(10): 1901–1914.
    CrossRefPubMed
  5. Neuhouser ML, Aragaki AK, Prentice RL, et al. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015; 1(5): 611–621.
    CrossRefPubMed
  6. Dal Maso L, Zucchetto A, Talamini R, et al. Prospective Analysis of Case-control studies on Environmental factors and health (PACE) study group. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer. 2008; 123(9): 2188–2194.
    CrossRefPubMed
  7. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412–423.
    CrossRefPubMed
  8. Kłęk S, Jankowski M, Kruszewski W, et al. Standardy leczenia żywieniowego w onkologii. Nowotwory. Journal of Oncology. 2015; 65(4): 320–337.
    CrossRef
  9. Cederholm T, Jensen GL, Correia MI, et al. GLIM Core Leadership Committee, GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle. 2019; 10(1): 207–217.
    CrossRefPubMed
  10. Deluche E, Leobon S, Desport JC, et al. Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer. 2018; 26(3): 861–868.
    CrossRefPubMed
  11. Zhang XM, Dou QL, Zeng Y, et al. Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review. BMC Cancer. 2020; 20(1): 172.
    CrossRefPubMed
  12. Villaseñor A, Ballard-Barbash R, Baumgartner K, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv. 2012; 6(4): 398–406.
    CrossRefPubMed
  13. Carneiro IP, Mazurak VC, Prado CM. Clinical Implications of Sarcopenic Obesity in Cancer. Curr Oncol Rep. 2016; 18(10): 62.
    CrossRefPubMed
  14. Yip C, Dinkel C, Mahajan A, et al. Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 2015; 6(4): 489–497.
    CrossRefPubMed
  15. Santa Mina D, Scheede-Bergdahl C, Gillis C, et al. Optimization of surgical outcomes with prehabilitation. Appl Physiol Nutr Metab. 2015; 40(9): 966–969.
    CrossRefPubMed
  16. Kłęk S et al. Protokół ERAS – sposoby odżywiania i leczenia żywieniowego pacjentów oddziału chirurgicznego. Protokół ERAS dla poprawy wyników leczenia. Sposoby odżywiania i leczenia żywieniowego pacjentów oddziału chirurgicznego. Medycyna Praktyczna. [Online] 01.04.2016. https://www.mp.pl/eras/wytyczne/show.html?id=132020.
  17. Macmillan Cancer Support et al. Macmillan Cancer Support, NIHR Cancer and Nutrition CPrehabilitation for people with cancer: Principles and guidance for prehabilitation within the management and support of people with cancer . [Online] 2019. www.macmillan.org.uk/assets/prehabilitationguidance-for-people-with-cancer.pdf.
  18. Durrand J, Singh SJ, Danjoux G. Prehabilitation. Clin Med (Lond). 2019; 19(6): 458–464.
    CrossRefPubMed
  19. EMA. Sumary of product characteristics - Tecentriq. 2023 update, EMEA/H/C/004143. https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq.
  20. Pamoukdjian F, Bouillet T, Lévy V, et al. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review. Clin Nutr. 2018; 37(4): 1101–1113.
    CrossRefPubMed
  21. Petrelli JM, Calle EE, Rodriguez C, et al. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002; 13(4): 325–332.
    CrossRefPubMed
  22. Petrelli JM, Calle EE, Rodriguez C, et al. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002; 13(4): 325–332.
    CrossRefPubMed
  23. Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021; 40(5): 2898–2913.
    CrossRefPubMed
  24. Moore DR, Churchward-Venne TA, Witard O, et al. Protein ingestion to stimulate myofibrillar protein synthesis requires greater relative protein intakes in healthy older versus younger men. J Gerontol A Biol Sci Med Sci. 2015; 70(1): 57–62.
    CrossRefPubMed
  25. Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care. 2009; 12(1): 86–90.
    CrossRefPubMed
  26. Jahani M, Noroznezhad F, Mansouri K. Arginine: Challenges and opportunities of this two-faced molecule in cancer therapy. Biomed Pharmacother. 2018; 102: 594–601.
    CrossRefPubMed
  27. Matos A, Carvalho M, Bicho M, et al. Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression. Nutrients. 2021; 13(12).
    CrossRefPubMed
  28. McGlory C, Calder PC, Nunes EA. The Influence of Omega-3 Fatty Acids on Skeletal Muscle Protein Turnover in Health, Disuse, and Disease. Front Nutr. 2019; 6: 144.
    CrossRefPubMed
  29. Fabian CJ, Kimler BF, Hursting SD. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Res. 2015; 17(1): 62.
    CrossRefPubMed
  30. Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Journal. 2012; 10(7).
    CrossRef
  31. Polskie Towarzystwo Żywienia Pozajelitowego, Dojelitowego i Metabolizmu. Standardy żywienia dojelitowego i pozajelitowego. Scietifica sp. z o.o., Kraków 2019.
  32. Weimann A, Braga M, Carli F, et al. ESPEN practical guideline: Clinical nutrition in surgery. Clin Nutr. 2021; 40(7): 4745–4761.
    CrossRefPubMed
  33. Temple-Oberle C, Shea-Budgell MA, Tan M, et al. ERAS Society. Consensus Review of Optimal Perioperative Care in Breast Reconstruction: Enhanced Recovery after Surgery (ERAS) Society Recommendations. Plast Reconstr Surg. 2017; 139(5): 1056e–1071e.
    CrossRefPubMed
  34. Moran J, Wilson F, Guinan E, et al. The preoperative use of field tests of exercise tolerance to predict postoperative outcome in intra-abdominal surgery: a systematic review. J Clin Anesth. 2016; 35: 446–455.
    CrossRefPubMed
  35. Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. JAMA. 2005; 293(20): 2479–2486.
    CrossRefPubMed
  36. Tew GA, Batterham AM, Colling K, et al. Randomized feasibility trial of high-intensity interval training before elective abdominal aortic aneurysm repair. Br J Surg. 2017; 104(13): 1791–1801.
    CrossRefPubMed
  37. Hojman P, Gehl J, Christensen JF, et al. Molecular Mechanisms Linking Exercise to Cancer Prevention and Treatment. Cell Metab. 2018; 27(1): 10–21.
    CrossRefPubMed
  38. Severinsen MC, Pedersen BK. Muscle-Organ Crosstalk: The Emerging Roles of Myokines. Endocr Rev. 2020; 41(4): 594–609.
    CrossRefPubMed
  39. Hennis PJ, Meale PM, Grocott MPW. Cardiopulmonary exercise testing for the evaluation of perioperative risk in non-cardiopulmonary surgery. Postgrad Med J. 2011; 87(1030): 550–557.
    CrossRefPubMed
  40. Gillis C, Carli F. Promoting Perioperative Metabolic and Nutritional Care. Anesthesiology. 2015; 123(6): 1455–1472.
    CrossRefPubMed
  41. Kincaid A. Cancer Prevention and Management Through Exercise and Weight Control. Physical Therapy. 2007; 87(5): 615–615.
    CrossRef
  42. Goyal A, Milner GE, Cimino-Mathews A, et al. Weight Gain after Hormone Receptor-Positive Breast Cancer. Curr Oncol. 2022; 29(6): 4090–4103.
    CrossRefPubMed
  43. Lima MT, de Carvalho KP, Mazzutti FS, et al. Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients. BMC Cancer. 2017; 17(1): 578.
    CrossRefPubMed
  44. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023; 401(10371): 105–117.
    CrossRefPubMed
  45. Nasiłowska-Adamska B. Profilaktyka i leczenie zaburzeń przewodu pokarmowego towarzyszących chemioterapii i radioterapii. Gastroenterologia Kliniczna. Postępy i Standardy. 2012. https://journals.viamedica.pl/gastroenterologia_kliniczna/article/view/29264.
  46. EMA. Sumary of product characteristics - KEYTRUDA. 2023, EMEA/H/C/003820. https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda#product-information-section.
  47. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012; 366(6): 520–529.
    CrossRefPubMed
  48. Swain SM, Miles D, Kim SB, et al. CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(4): 519–530.
    CrossRefPubMed
  49. Johannes CM, Musser ML. Anorexia and the Cancer Patient. Vet Clin North Am Small Anim Pract. 2019; 49(5): 837–854.
    CrossRefPubMed
  50. Mello AT, Borges DS, de Lima LP, et al. Effect of oral nutritional supplements with or without nutritional counselling on mortality, treatment tolerance and quality of life in head-and-neck cancer patients receiving (chemo)radiotherapy: a systematic review and meta-analysis. Br J Nutr. 2021; 125(5): 530–547.
    CrossRefPubMed
  51. Nathan CAO, Asarkar AA, Entezami P, et al. Current management of xerostomia in head and neck cancer patients. Am J Otolaryngol. 2023; 44(4): 103867.
    CrossRefPubMed
  52. Moschen AR, Sammy Y, Marjenberg Z, et al. The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients. Curr Oncol Rep. 2022; 24(7): 861–874.
    CrossRefPubMed
  53. Dzierżanowski T, Mercadante S. Constipation in Cancer Patients - an Update of Clinical Evidence. Curr Treat Options Oncol. 2022; 23(7): 936–950.
    CrossRefPubMed
  54. Ravasco P. Aspects of taste and compliance in patients with cancer. Eur J Oncol Nurs. 2005; 9 Suppl 2: S84–S91.
    CrossRefPubMed
  55. Elad S, Cheng KK, Lalla RV, et al. Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020; 126(19): 4423–4431.
    CrossRefPubMed
  56. Nyrop KA, Williams GR, Muss HB, et al. Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence? Breast Cancer Res Treat. 2016; 158(2): 203–217.
    CrossRefPubMed
  57. Raghavendra A, Sinha AK, Valle-Goffin J, et al. Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors. Clin Breast Cancer. 2018; 18(1): e7–ee13.
    CrossRefPubMed
  58. Cortes J, Rugo HS, Cescon DW, et al. KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022; 387(3): 217–226.
    CrossRefPubMed
  59. Wojciechowska U. Nowotwory złośliwe w Polsce w 2014 roku. Centrum Onkologii — Instytut, Warszawa .
  60. Heasman KZ, Sutherland HJ, Campbell JA, et al. Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 1985; 5(2): 195–200.
    CrossRefPubMed
  61. McInnes JA, Knobf MT. Weight gain and quality of life in women treated with adjuvant chemotherapy for early-stage breast cancer. Oncol Nurs Forum. 2001; 28(4): 675–684.
    PubMed
  62. Schwartz AL. Exercise and weight gain in breast cancer patients receiving chemotherapy. Cancer Pract. 2000; 8(5): 231–237.
    CrossRefPubMed
  63. Sobotka L, Allison SP, Forbes A, et al. Podstawy Żywienia Klinicznego. Edycja Czwarta. Wydanie polskie. Scientifica Sp. z o.o., Kraków 2013.
  64. Torregrosa C, Chorin F, Beltran EE, et al. Physical Activity as the Best Supportive Care in Cancer: The Clinician's and the Researcher's Perspectives. Cancers (Basel). 2022; 14(21).
    CrossRefPubMed
  65. Kumar N, Allen KA, Riccardi D, et al. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit? Breast Cancer Res Treat. 2004; 83(2): 149–159.
    CrossRefPubMed
  66. Demark-Wahnefried W, Peterson BL, Winer EP, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2001; 19(9): 2381–2389.
    CrossRefPubMed
  67. Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. 4th ed. IARC Press, Lyon 2012.
  68. Shao M, Hollar S, Chambliss D, et al. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Mol Cancer Ther. 2012; 11(7): 1576–1586.
    CrossRefPubMed
  69. Dębska S, Potemski P. Leczenia hormonalne chorych na raka piersi z nadekspresją receptora HER2. Onkol Prak Klin. 2010; 6(6): 301–310.
  70. Xing MY, Xu SZ, Shen P. Effect of low-fat diet on breast cancer survival: a meta-analysis. Asian Pac J Cancer Prev. 2014; 15(3): 1141–1144.
    CrossRefPubMed
  71. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 v1.0 IARC. CancerBase No. 11. International Agency for Research on Cancer, Lyon 2012.
  72. Nowotworów Krajowy Rejestr. Czym jest rak piersi? [Online] 2021. https://onkologia.org.pl/pl/nowotwor-piersi-u-kobiet-czym-jest#page-main-image.
  73. O'Brien J, Martinson H, Durand-Rougely C, et al. Macrophages are crucial for epithelial cell death and adipocyte repopulation during mammary gland involution. Development. 2012; 139(2): 269–275.
    CrossRefPubMed
  74. Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1993; 11(7): 1418–1429.
    CrossRefPubMed
  75. Lee E, Kady V, Han E, et al. Healthy Eating and Mortality among Breast Cancer Survivors: A Systematic Review and Meta-Analysis of Cohort Studies. Int J Environ Res Public Health. 2022; 19(13): 7579.
    CrossRefPubMed
  76. Parl FF, Egan KM, Li C, et al. Estrogen exposure, metabolism, and enzyme variants in a model for breast cancer risk prediction. Cancer Inform. 2009; 7: 109–121.
    CrossRefPubMed
  77. Paluch-Shimon S, Cardoso F, Sessa C, et al. ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016; 27(suppl 5): v103–v110.
    CrossRefPubMed
  78. Feng TY, Azar F, Dreger S, et al. Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors. Cancer Immunology Research. 2022; 10(11): 1309–1325.
    CrossRef
  79. Oh B, Boyle F, Pavlakis N, et al. Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. Front Oncol. 2021; 11: 706331.
    CrossRefPubMed
  80. Biela A, Pacholska-Bogalska J. Nowotwory hormonozależne u kobiet. Nowa Medycyna. 2012 (4): 76–81. www.czytelniamedyczna.pl/4296,nowotwory-hormonozalezne-u-kobiet.html.
  81. Parida S, Wu S, Siddharth S, et al. A Procarcinogenic Colon Microbe Promotes Breast Tumorigenesis and Metastatic Progression and Concomitantly Activates Notch and β-Catenin Axes. Cancer Discov. 2021; 11(5): 1138–1157.
    CrossRefPubMed
  82. Fernández MF, Reina-Pérez I, Astorga JM, et al. Breast Cancer and Its Relationship with the Microbiota. Int J Environ Res Public Health. 2018; 15(8).
    CrossRefPubMed
  83. Gałęcka M. Probiotyki w onkologii. Konferencja Mikrobiota, Szczecin 2019.
  84. Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer. 2016; 57: 58–67.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna